Breast Cancer Research and Treatment

, Volume 120, Issue 2, pp 437–439 | Cite as

Personal breast: customizing agents and biomarkers for optimal adjuvant endocrine therapy

  • Aditya Bardia
  • Vered Stearns
Invited Commentary

Adjuvant endocrine therapy remains the most important systemic intervention recommended to women with breast cancer whose tumors contain the estrogen receptor (ER) or progesterone receptor. Results from over a dozen prospective clinical trials have consistently demonstrated that the incorporation of the third generation aromatase inhibitors (AIs), including anastrozole, letrozole, and exemestane, in the adjuvant setting, instead of or in sequence with tamoxifen, were superior to 5 years of single agent tamoxifen in reducing breast cancer-related relapse or death [1]. In addition to a small superiority in efficacy, AIs are associated with a slightly different safety profile compared to tamoxifen. Biomarkers that could help predict efficacy and safety to specific endocrine interventions or even to specific agents are greatly needed and could be used to personalize various endocrine manipulations for individual women. Predictive biomarkers may be tumor or host specific, and may be...


Tamoxifen Breast Cancer Risk Letrozole Breast Density Benign Breast Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Conflict of interest

Dr. Stearns received investigator-initiated research grants from Novartis and Pfizer, and honoraria from Astra Zeneca.


  1. 1.
    Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J et al (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23(3):619–629CrossRefPubMedGoogle Scholar
  2. 2.
    Wolfe JN (1976) Breast patterns as an index of risk for developing breast cancer. AJR Am J Roentgenol 126(6):1130–1137PubMedGoogle Scholar
  3. 3.
    Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ (1998) Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev 7(12):1133–1144PubMedGoogle Scholar
  4. 4.
    Greendale GA, Palla SL, Ursin G, Laughlin GA, Crandall C, Pike MC, Reboussin BA (2005) The association of endogenous sex steroids and sex steroid binding proteins with mammographic density: results from the Postmenopausal Estrogen/Progestin Interventions Mammographic Density Study. Am J Epidemiol 162(9):826–834CrossRefPubMedGoogle Scholar
  5. 5.
    Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G (2003) Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 95(1):30–37PubMedCrossRefGoogle Scholar
  6. 6.
    Atkinson C, Warren R, Bingham SA, Day NE (1999) Mammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen. Cancer Epidemiol Biomarkers Prev 8(10):863–866PubMedGoogle Scholar
  7. 7.
    Cuzick J, Warwick J, Pinney E, Warren RM, Duffy SW (2004) Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst 96(8):621–628PubMedGoogle Scholar
  8. 8.
    Cigler T, Tu D, Yaffe MJ, Findlay B, Verma S, Johnston D, Richardson H, Hu H, Qi S, Goss PE (2009) A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women. Breast Cancer Res Treat. doi: 10.1007/s10549-009-0662-0 PubMedGoogle Scholar
  9. 9.
    Fabian CJ, Kimler BF, Zalles CM, Khan QJ, Mayo MS, Phillips TA, Simonsen M, Metheny T, Petroff BK (2007) Reduction in proliferation with six months of letrozole in women on hormone replacement therapy. Breast Cancer Res Treat 106(1):75–84CrossRefPubMedGoogle Scholar
  10. 10.
    Vachon CM, Ingle JN, Suman VJ, Scott CG, Gottardt H, Olson JE, Goss PE (2007) Pilot study of the impact of letrozole vs. placebo on breast density in women completing 5 years of tamoxifen. Breast 16(2):204–210CrossRefPubMedGoogle Scholar
  11. 11.
    McTiernan A, Chlebowski RT, Martin C, Peck JD, Aragaki A, Pisano ED, Wang CY, Johnson KC, Manson JE, Wallace RB et al (2009) Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women’s health initiative randomized trial. J Clin Oncol 27(36):6135–6143CrossRefPubMedGoogle Scholar
  12. 12.
    Hattar R, Maller O, McDaniel S, Hansen KC, Hedman KJ, Lyons TR, Lucia S, Wilson RS Jr, Schedin P (2009) Tamoxifen induces pleiotrophic changes in mammary stroma resulting in extracellular matrix that suppresses transformed phenotypes. Breast Cancer Res 11(1):R5CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  1. 1.Sidney Kimmel Comprehensive Cancer Center Johns Hopkins School of MedicineBaltimoreUSA
  2. 2.Sidney Kimmel Comprehensive Cancer Center Johns Hopkins School of MedicineBaltimoreUSA

Personalised recommendations